TADA3

Across TCGA pan-cancer cohorts, TADA3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TADA3 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TADA3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TADA3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where TADA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	1.000	0.928	.022	13	view →
LUAD	OS	Quartile	II,III,IV	0.799	0.344	.019	9	view →
PDAC	OS	Median	III,IV	0.332	0.819	.003	7	view →
GBM	DFS	Median	All	0.272	0.464	.005	7	view →
HNSC	OS	Quartile	All	0.604	0.822	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TADA3–LSCC (OS)

Open the LSCC breakdown →